{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-23-000043","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.150503+00:00","generated_at":"2026-06-19T23:00:00.911668+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Praxis reports FY2022 net loss $214M; cash $100.5M, runway into 1Q24","bullets":["Cash and investments $100.5M as of Dec 31, 2022, down from $275.9M; expected to fund ops into 1Q24.","Net loss FY2022 $214.0M vs $167.1M; Q4 net loss $41.2M.","R&D expense FY2022 $155.0M, up from $120.3M, reflecting Cerebrum/Solidus platform spending.","Phase 2b ulixacaltamide topline results for essential tremor expected in 1Q23.","Entered UCB collaboration for KCNT1 program; up to ~$100M in milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-23-000043","json":"https://secwatch.observer/filing/0001689548-23-000043.json","markdown":"https://secwatch.observer/filing/0001689548-23-000043.md","text":"https://secwatch.observer/filing/0001689548-23-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/0001689548-23-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/prax-20230207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:00:00.911668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cc28873d927525eced323ed6135c333b0aceb72","claim":"Praxis Precision Medicines, Inc. reported financial results for fourth quarter and full year 2022.","evidence_excerpt":"On February 7, 2023 , Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/0001689548-23-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}